Cancer Clinical Trials 2023

Browse 100 Cancer Medical Studies Across 238 Cities

6 Phase 3 Trial · 976 Cancer Clinics

Reviewed by Michael Gill, B. Sc.
10 Cancer Clinical Trials Near Me
Top Hospitals for Cancer Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
10Active Trials
260All Time Trials for Cancer
1977First Cancer Trial
Image of GSK Investigational Site in Texas.
GSK Investigational Site
Dallas
8Active Trials
16All Time Trials for Cancer
2008First Cancer Trial
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
8Active Trials
176All Time Trials for Cancer
1999First Cancer Trial
Image of The University of Texas MD Anderson Cancer Center in Texas.
The University of Texas MD Anderson Cancer Center
Houston
8Active Trials
88All Time Trials for Cancer
2006First Cancer Trial
Image of GSK Investigational Site in Ontario.
GSK Investigational Site
Toronto
8Active Trials
25All Time Trials for Cancer
2014First Cancer Trial
Top Cities for Cancer Clinical Trials
Image of New York in New York.
New York
45Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Houston in Texas.
Houston
45Active Trials
The University of Texas MD Anderson Cancer CenterTop Active Site
Cancer Clinical Trials by Phase of Trial
N/A Cancer Clinical Trials
13Active Cancer Clinical Trials
13Number of Unique Treatments
31Number of Active Locations
Cancer Clinical Trials by Age Group
< 65 Cancer Clinical Trials
4Active Cancer Clinical Trials
Most Recent Cancer Clinical TrialsTop Treatments for Cancer Clinical Trials
Treatment Name
Active Cancer Clinical Trials
All Time Trials for Cancer
First Recorded Cancer Trial
Treatment
6
6
1997
Gemcitabine
2
81
2001
EMB-01
2
2
2018
BI 907828
2
2
2018
ATLCAR.CD30 cells
2
2
2016
Recently Completed Studies with FDA Approved Treatments for Cancer
Treatment
Year
Sponsor
pegsitacianine
2022
OncoNano Medicine, Inc.
64Cu-SAR-bisPSMA
2022
Clarity Pharmaceuticals Ltd
ADG116
2022
Adagene Inc
Pembrolizumab
2021
HiberCell, Inc.
Capivasertib
2021
AstraZeneca
MRTX849
2021
Mirati Therapeutics Inc.
M4076
2021
EMD Serono Research & Development Institute, Inc.
AMG 994
2021
Amgen
mRNA-1273
2021
National Cancer Institute (NCI)
parsaclisib
2021
Incyte Corporation

What Are Cancer Clinical Trials?

Cancer is a condition whereby standard cell division is interrupted or altered causing cells to grow uncontrollably and spread to other parts of the body.

The growth of these mutated cells causes various conditions like lymphomas, leukemias, sarcomas, and carcinomas. Cancer is the umbrella term for these various conditions and comprises multiple diseases.

Cancer clinical trials refer to research or studies performed by medical health professionals to test new treatments, diagnosis methodologies, curative procedures, and ways to manage these conditions. The trials can be undertaken by patients with all types of cancers at any stage.

Why Is Cancer Being Studied Through Clinical Trials?

Cancer is a prevalent and deadly condition. Cancers are also one of the most prevalent causes of death, with almost 10,000 deaths recorded for patients with cancer in 2020 alone. It's also estimated that over 18 million people were diagnosed in 2020. Medical professionals can treat the early stages of cancer more effectively. However, later stages (II, II, or IV) have a progressively worse prognosis for patients.

Researchers need to perform clinical trials to better understand what triggers mutations, how cancer is formed and spread within the body, and how to treat, prevent, and manage the condition. It’s essential to study the condition to gather more information on it in the hopes of curing and preventing it in future patients.

The most common clinical trials for cancer are diagnostic trials. They use imaging, scanning, and blood tests to find better ways of diagnosing patients and understanding the diagnostic process.

Other trials include those using radiation to shrink or eliminate cancer cells; behavioral therapies to help cancer patients improve their overall well-being and manage their condition; and new medications drugs to stunt tumor growth or eliminate it.

What Are The Types of Treatments Available For Cancer?

Various treatments are available for cancer, including chemotherapy, radiation therapy, hormone therapy, immunotherapy, photodynamic therapy, stem cell transplants, targeted therapy and surgery. The types of treatment available depend on the type of cancer and how advanced it is.

Some people with cancer will only have one treatment, but many have a combination of treatments such as surgery with chemotherapy.

What Are Some Recent Breakthrough Clinical Trials For Cancer?

There have been some incredible breakthroughs in cancer research in the last few years alone. Notably, there are two studies from 2023 that have significantly advanced the field of cancer research:

2023: Immunotherapy Treatment – A New York's Memorial Sloan Kettering Cancer Center trial revealed that using an immunotherapy drug (dostarlimab) may help eliminate rectal adenocarcinomas. Dostarlimab was initially designed for patients with endometrial cancers. All twelve patients diagnosed with stage II and III rectal cancers had a 100% success rate and were in remission after using the treatment for six months.

2023: Genomic Research – Researchers from the University of Cambridge and Cambridge University Hospitals analyzed the genomic make-up and data from over 12,000 cancer patients. By studying each patient's genes and their cancer mutation patterns, researchers could identify nearly 60 individual mutational signatures. This is the most extensive genomic study on the condition to date.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: September 6th, 2023

References1 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. https://pubmed.ncbi.nlm.nih.gov/284346482 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review. https://pubmed.ncbi.nlm.nih.gov/278950583 Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. https://pubmed.ncbi.nlm.nih.gov/278950584 Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004. Erratum In: Ann Intern Med. 2008 Oct 7;149(7):519. Ann Intern Med. 2021 Apr;174(4):584. https://pubmed.ncbi.nlm.nih.gov/169089155 Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. Erratum in: Ann Intern Med. 2008 Oct 7;149(7):519. Erratum in: Ann Intern Med. 2021 Apr;174(4):584. https://pubmed.ncbi.nlm.nih.gov/169089156 Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D, Berger A, Shapiro G, Huszar D. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 2022 May 5;139(18):2770-2781. doi: 10.1182/blood.2021014267. https://pubmed.ncbi.nlm.nih.gov/352267397 Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010 Nov;9(11):843-56. doi: 10.1038/nrd3216. Epub 2010 Oct 29. Review. https://pubmed.ncbi.nlm.nih.gov/210310018 Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012 Mar;24(2):112-24. doi: 10.1016/j.clon.2011.11.004. Epub 2011 Nov 29. Review. https://pubmed.ncbi.nlm.nih.gov/221306309 Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010 Nov;9(11):843-56. doi: 10.1038/nrd3216. Epub 2010 Oct 29. https://pubmed.ncbi.nlm.nih.gov/2103100110 Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012 Mar;24(2):112-24. doi: 10.1016/j.clon.2011.11.004. Epub 2011 Nov 29. https://pubmed.ncbi.nlm.nih.gov/22130630